DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Abstract Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-08-01
|
| Series: | Military Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40779-022-00410-2 |
| _version_ | 1818000755362103296 |
|---|---|
| author | Michael Razavi Ying-Ying Wei Xiao-Quan Rao Ji-Xin Zhong |
| author_facet | Michael Razavi Ying-Ying Wei Xiao-Quan Rao Ji-Xin Zhong |
| author_sort | Michael Razavi |
| collection | DOAJ |
| description | Abstract Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food and Drug Administration (FDA) and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints. As a result, since 2008, the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety. The present review article strives to assess the safety and benefits of incretin-based therapy, a new class of antidiabetic drug, on the health of patient cardiovascular systems. In the process, this review will also provide a physiological overview of the incretin system and how key components function in T2DM. |
| first_indexed | 2024-04-14T03:25:46Z |
| format | Article |
| id | doaj.art-d8f3f4f51e8f47c884d0ced18e16a237 |
| institution | Directory Open Access Journal |
| issn | 2054-9369 |
| language | English |
| last_indexed | 2024-04-14T03:25:46Z |
| publishDate | 2022-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Military Medical Research |
| spelling | doaj.art-d8f3f4f51e8f47c884d0ced18e16a2372022-12-22T02:15:11ZengBMCMilitary Medical Research2054-93692022-08-019111510.1186/s40779-022-00410-2DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefitsMichael Razavi0Ying-Ying Wei1Xiao-Quan Rao2Ji-Xin Zhong3Tulane University School of MedicineDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and TechnologyDepartment of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and TechnologyDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and TechnologyAbstract Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food and Drug Administration (FDA) and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints. As a result, since 2008, the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety. The present review article strives to assess the safety and benefits of incretin-based therapy, a new class of antidiabetic drug, on the health of patient cardiovascular systems. In the process, this review will also provide a physiological overview of the incretin system and how key components function in T2DM.https://doi.org/10.1186/s40779-022-00410-2Glucagon-like peptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsType 2 diabetes mellitusCardiovascular outcome |
| spellingShingle | Michael Razavi Ying-Ying Wei Xiao-Quan Rao Ji-Xin Zhong DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits Military Medical Research Glucagon-like peptide-1 receptor agonists Dipeptidyl peptidase-4 inhibitors Type 2 diabetes mellitus Cardiovascular outcome |
| title | DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits |
| title_full | DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits |
| title_fullStr | DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits |
| title_full_unstemmed | DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits |
| title_short | DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits |
| title_sort | dpp 4 inhibitors and glp 1ras cardiovascular safety and benefits |
| topic | Glucagon-like peptide-1 receptor agonists Dipeptidyl peptidase-4 inhibitors Type 2 diabetes mellitus Cardiovascular outcome |
| url | https://doi.org/10.1186/s40779-022-00410-2 |
| work_keys_str_mv | AT michaelrazavi dpp4inhibitorsandglp1rascardiovascularsafetyandbenefits AT yingyingwei dpp4inhibitorsandglp1rascardiovascularsafetyandbenefits AT xiaoquanrao dpp4inhibitorsandglp1rascardiovascularsafetyandbenefits AT jixinzhong dpp4inhibitorsandglp1rascardiovascularsafetyandbenefits |